- Home
- IBOC vs NAMS Comparison
IBOC vs NAMS Comparison
Compare IBOC & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBOC | NAMS |
|---|---|---|
| Founded | 1966 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.0B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IBOC | NAMS |
|---|---|---|
| Price | $66.69 | $34.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $85.00 | $46.40 |
| AVG Volume (30 Days) | 314.2K | ★ 1.0M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | ★ 5.13 | N/A |
| EPS | ★ 6.76 | N/A |
| Revenue | ★ $821,716,000.00 | $35,243,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.83 | ★ N/A |
| Revenue Growth | 2.80 | ★ 4.91 |
| 52 Week Low | $54.11 | $14.06 |
| 52 Week High | $73.66 | $42.00 |
Technical Indicators
Market Signals| Indicator | IBOC | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 38.82 | 44.12 |
| Support Level | $67.61 | $33.91 |
| Resistance Level | $69.62 | $36.00 |
| Average True Range (ATR) | 1.46 | 1.50 |
| MACD | -0.63 | -0.03 |
| Stochastic Oscillator | 13.17 | 39.91 |
Price Performance
Historical ComparisonAbout IBOC International Bancshares Corporation
International Bancshares Corp is a multibank financial holding company. The company provides commercial and retail banking services in Texas and Oklahoma. The services provided by the bank include checking, savings, bank cards, lending, insurance, mortgage, investments, and other services.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.